← Research ProtocolsPemvidutide
STUDIED EXPOSURE MAP / 2025
Pemvidutide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / RANDOMIZED PHASE 2JOURNAL OF HEPATOLOGYSTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
1.2 mg
SC · once weekly
1.8 mg
SC · once weekly
2.4 mg
SC · once weekly
Context: The trial randomized participants to three weekly dose groups or placebo. The high-dose arm used protocol-defined escalation.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / JOURNAL OF HEPATOLOGY
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2025
01 / DESIGNRandomized · double-blind · placebo-controlled
02 / POPULATION / MODELAdults with MASLD, BMI ≥28 kg/m² and liver fat ≥10%
03 / ROUTESubcutaneous · once weekly
04 / TIMEFRAME12 weeks in the core study
05 / PRIMARY QUESTIONChange in liver fat content
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Broader research index. This entity is not presented here as an ENHANCED catalogue compound.
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.